Endogenous GSK-3/Shaggy regulates bidirectional axonal transport of the Amyloid Precursor Protein

Author :C. Weaver, C. Leidel, L. Szpankowski, N. M. Farley, G. T. Shubeita, L.S.B. Goldstein
Publisher :Traffic
Volume :14
Number :3
Pages :295-308
Year :2013
Note :http://dx.doi.org/10.1111/tra.12037
Neurons rely on microtubule (MT) motor proteins such as kinesin-1 and dynein to transport essential cargos between the cell body and axon terminus. Defective axonal transport causes abnormal axonal cargo accumulations and is connected to neurodegenerative diseases, including Alzheimer’s disease (AD). Glycogen synthase kinase 3 (GSK-3) has been proposed to be a central player in AD and to regulate axonal transport by the MT motor protein kinesin-1. Using genetic, biochemical and biophysical approaches in Drosophila melanogaster, we ?nd that endogenous GSK-3 is a required negative regulator of both kinesin-1-mediated and dynein-mediated axonal transport of the amyloid precursor protein (APP), a key contributor to AD pathology. GSK-3 also regulates transport of an unrelated cargo, embryonic lipid droplets. By measuring the forces motors generate in vivo, we ?nd that GSK-3 regulates transport by altering the activity of kinesin-1 motors but not their binding to the cargo. These ?ndings reveal a new relationship between GSK-3 and APP, and demonstrate that endogenous GSK-3 is an essential in vivo regulator of bidirectional APP transport in axons and lipid droplets in embryos. Furthermore, they point to a new regulatory mechanism in which GSK-3 controls the number of active motors that are moving a cargo.